Dee and Jimmy Haslam pledged $12.5 million to accelerate CLL and rare blood‑cancer research, sending $10M to the Oxford‑Harrington centre and $2.5M to UH Seidman.

The Coast Guard will run autonomous "sail drones" across the five Great Lakes from May–October to bolster patrols and gather weather and traffic data.

Crain's roundup of Q1 2026 VC rounds shows Ohio startups pulled in several big checks, led by a $30M Series B for Solon-based Eagle Wireless.

A tenfold speed boost at Cleveland Clinic’s on‑site quantum system and a $2M Wellcome Leap prize are accelerating quantum drug‑discovery work and local training programs.

Cleveland‑Cliffs signed a three‑year deal with Palantir to bring AI into production planning and order workflows across its mills, a move that promises efficiency and raises local questions.

An Ohio University analysis of Cirque du Soleil medical records found 354 concussions across 2.7 million exposures — about 1.3 per 10,000 — lower than many expect.

Case Western Reserve landed a $3.1M NICHD grant to test three ways to restore touch in people with quadriplegia. The trial will use volunteers already implanted with electrodes.

Case Western Reserve tapped Susan Hagness, a UW–Madison electrical engineer, as the Case School of Engineering's first woman dean; she starts July 1, 2026.

Cleveland Fire demoed F-500, a water additive for lithium‑ion and metal fires, and said crews will carry it in 5‑gallon tanks on every rig.

An Oakwood Village woman says a Cleveland Clinic gene‑editing trial has cut years of sickle‑cell pain and hospital visits. Early results from the RUBY study show promising improvements for participants.

An Ohio State study using objective lab tests of 60 adults finds long COVID often causes measurable smell, hearing, balance and cognitive problems, with age and severe illness linked to worse outcomes.

A NEJM‑published LATITUDE trial shows monthly cabotegravir‑rilpivirine injections reduced regimen failures among people who struggle with daily oral HIV therapy. University of Cincinnati clinicians were among the lead sites.

Researchers at Case Western and MetroHealth developed CD133‑targeted RNA nanoparticles that silence the FTO gene and slowed drug‑resistant leukemia in lab models.